The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
Subscribe To Our Newsletter & Stay Updated
